Current diabetes reports · 2026
Omega-3 and Omega-6 Fatty Acids and Cardiovascular Outcomes in Diabetes - A Review of Current Evidence.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wattick Rachel A, McNabb Tara B, Hudson Alana G
Аннотация
PURPOSE OF REVIEW: Cardiovascular disease remains the leading cause of morbidity and mortality among individuals with diabetes. This review examines recent evidence on the effects of omega-3 and omega-6 fatty acids on cardiovascular outcomes in diabetes.
RECENT FINDINGS: Cardiovascular outcomes trials demonstrate heterogeneous effects of omega-3 supplementation. High-dose purified eicosapentaenoic acid (EPA) has reduced cardiovascular events in selected high-risk populations, whereas low-dose combined EPA and docosahexaenoic acid (EPA + DHA) formulations have generally shown limited benefit. Omega-6 fatty acid evidence remains more limited, with most studies evaluating lipid markers rather than clinical cardiovascular outcomes. More investigation is needed into the potential benefits and optimal formulation of omega-3 fatty acids for cardiovascular outcomes in diabetes. Omega-6 fatty acids appear neutral or beneficial when replacing saturated fats, but their effects on clinical cardiovascular outcomes among individuals with diabetes remain uncertain. Future research should prioritize diabetes-specific trials examining patient characteristics, background diet, fatty acid formulation, dose, and long-term safety.
RECENT FINDINGS: Cardiovascular outcomes trials demonstrate heterogeneous effects of omega-3 supplementation. High-dose purified eicosapentaenoic acid (EPA) has reduced cardiovascular events in selected high-risk populations, whereas low-dose combined EPA and docosahexaenoic acid (EPA + DHA) formulations have generally shown limited benefit. Omega-6 fatty acid evidence remains more limited, with most studies evaluating lipid markers rather than clinical cardiovascular outcomes. More investigation is needed into the potential benefits and optimal formulation of omega-3 fatty acids for cardiovascular outcomes in diabetes. Omega-6 fatty acids appear neutral or beneficial when replacing saturated fats, but their effects on clinical cardiovascular outcomes among individuals with diabetes remain uncertain. Future research should prioritize diabetes-specific trials examining patient characteristics, background diet, fatty acid formulation, dose, and long-term safety.